Apogee Therapeutics Advances Clinical Trials for APG333

The latest announcement is out from Apogee Therapeutics, Inc. ( (APGE) ).

Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial for APG333, a promising monoclonal antibody designed to treat asthma, COPD, and broader inflammatory conditions. This trial will explore the safety and effectiveness of APG333, which targets thymic stromal lymphopoietin, a key player in respiratory inflammation. The company is optimistic about the combination of APG333 with another antibody, APG777, to enhance treatment outcomes, with interim results expected in the second half of 2025.

For detailed information about APGE stock, go to TipRanks’ Stock Analysis page.